Ticker

Recommendation follows an Article 20 non-pharmacovigilance procedure  Patients currently on TAVNEOS treatment should consult their treating physician   ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the…

SYDNEY, June 12, 2026 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, and Adbri announce the delivery of MV Yampu, the world's first battery-powered self-unloading bulk carrier. The vessel was officially delivered at Jiangjiang Nanyang Shipyard on June 5, 2026, and has now departed on its maiden voyage to commence operations for Adbri in Birkenhead, South…

Australia's drug regulator ​said on Wednesday ‌it was notified by ​biopharmaceutical ​giant CSL's unit Seqirus ⁠that ​it will be ​discontinuing all strengths of their ​Benpen injection ​products progressively due ‌to ⁠commercial reasons.

CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by FY28, with 60% of FY26 savings already implemented. Vifor segment delivers robust growth, offsetting iron franchise declines; new products like ANDEMBRY and HEMGENIX drive future momentum.